To better yield and scale, Glenmark passes the benefits to patients by reducing the price of oral antiviral FabiFlu® by 27 % in India
- The new MRP is INR 75 per tab from the earlier INR 103 per tab
- Glenmark’s price reduction aims to make FabiFlu® further accessible for COVID-19 patients across the country
Chennai , India; July 15, 2020: Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical com pany, has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu® to closely m onitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral, as part of an open label, multicenter, single arm study.
Further, Glenmark has announced a price reduction of 27% for FabiFlu®. The new MRP is INR 75 per tab from the earlier INR 103 per tab. The price reduction has been made possible through benefits gained from higher yi elds and better scale, as both the API and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country.
Glenmark has successfully developed the active pharmaceutical ingredient (API) and the formulation for Fa bi Flu® through its own in-house R&D team within the country, ensuring self-reliance with regard to long-term production and manufacturing. The API is manufactured at the Gujarat production facility which is USFDA & MHRA–UK approved. The formulation product is manufactured at the facility in Himachal Pradesh, which is also USFDA and MHRA-UK approved.
Commenting on these developments, Mr. Alok Malik, Senior Vice President & Head – India business, Glenmark Pharmaceuticals Ltd., said, “We expect this post marketing surveillance study to shed more light on the drug’s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu®. Our priority from the start of this pandemic has been to offer patients in India an effective treatment for COVID-19, while also ensuring accessibility to the masses. Our internal research shows us that we launched FabiFlu® in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country.”
